Submission Based on Positive Results from Pivotal Phase 3 SORAYA Trial WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 29, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has submitted a Biologics
Conference Call to be Held at 8 a.m. ET on Monday, September 30 WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory
Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19 Investor Event to be Held Sunday, March 20 at 7:30 am MST WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 10, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- ImmunoGen Inc.
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three abstracts highlighting two of the Company's experimental ADC therapies, IMGN632 and IMGN779, have been
Phase 1 Data for IMGN779 and IMGN632 to be Highlighted in Oral Presentations at ASH WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts
Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs)
Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75 million upfront payment, up to $100 million in research support, a co-commercialization option, and potential future opt-in fees, milestones and royalties